Acquired Company

Ironwood Pharmaceuticals completed the squeeze-out merger with VectivBio on December 12, 2023, with all remaining VectivBio ordinary shares cancelled and converted into the right to receive $17.00 per share in cash.

VectivBio Holding AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in innovative therapies for rare diseases. The company has developed a strong pipeline of biologics and advanced therapeutic modalities designed to meet significant unmet medical needs in this niche market. By prioritizing strategic partnerships and clinical excellence, VectivBio aims to position itself as a frontrunner in the biopharmaceutical sector, focusing on delivering transformative treatments that improve the quality of life for patients facing rare conditions. Show more

Location: AESCHENVORSTADT 36, BASEL, SWITZERLAND, 4051, USA | Website: https://vectivbio.com | Industry: PHARMACEUTICALS | Sector: HEALTHCARE

Market Cap

1.058B

52 Wk Range

$0.00 - $0.00

Previous Close

$16.85

Open

$16.85

Volume

N/A

Day Range

$16.85 - $16.85

Enterprise Value

0.00

Cash

221.4M

Avg Qtr Burn

N/A

Insider Ownership

4.50%

Institutional Own.

83.80%

Qtr Updated

03/31/23

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date